Immunology and Microbiology
West Nile Virus
100%
Viral Disease
96%
Severe Acute Respiratory Syndrome Coronavirus 2
59%
Virus
51%
Monoclonal Antibody
43%
Dengue Virus
40%
Flavivirus
35%
Epitope
35%
Neutralization
35%
interferon
34%
Zika Virus
33%
Neutralizing Antibody
31%
Chikungunya Virus
27%
Alphavirus
23%
Immunity
20%
Spike
20%
Cytotoxic T-Cell
19%
Central Nervous System
18%
Human Monoclonal Antibody
17%
Immune Response
15%
Viral Replication
15%
Receptor Binding
13%
Glycoprotein
13%
Antibody Response
13%
T Cell
12%
Dengue Fever
12%
Virion
12%
Innate Immune System
11%
B Cell
11%
Infectious Agent
11%
Omicron Coronavirus Variant
10%
COVID-19
10%
Encephalitis
9%
RNA Virus
9%
Wild Type
8%
Serotype
8%
Viral Load
8%
Macrophage
7%
Dendritic Cell
7%
IRF3
7%
Interferon-Stimulated Gene
7%
Lineages
7%
Fc Receptor
7%
Adaptive Immune System
7%
Viral Entry
6%
Mouse Model
6%
Cryo-Electron Microscopy
6%
Virus Strain
6%
Humoral Immunity
6%
Viral Envelope
6%
Keyphrases
West Nile Virus
87%
COVID-19
55%
West Nile Virus Infection
54%
Monoclonal Antibody
50%
Zika Virus
39%
Dengue Virus
38%
Virus
37%
Flavivirus
35%
Chikungunya Virus (CHIKV)
31%
Neutralizing Antibodies
25%
Epitope
24%
Alphavirus
20%
Zika Virus Infection
20%
Interferon-α (IFN-α)
18%
Central Nervous System
18%
CD8+ T Cells
16%
Virus Pathogenesis
15%
Innate Immune Response
14%
Receptor-binding Domain
14%
Type I Interferon
13%
Dengue Infection
13%
Virion
12%
Viral Infection
12%
Antibody Response
11%
Human Antibody
11%
Non-structural Protein
11%
E Protein
11%
Stimulator of Interferon Genes (STING)
11%
Envelope Protein
10%
Antiviral Activity
10%
Virus Infection
10%
Pregenomic RNA (pgRNA)
10%
SARS-CoV-2 Infection
9%
Flavivirus Infection
9%
Chikungunya Virus Infection
9%
Spike Protein
9%
Dengue
8%
Interferon Regulatory Factor 3 (IRF3)
8%
Immune Response
8%
Neutralizing Monoclonal Antibody
8%
T Cells
8%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
7%
Viral
7%
Angiotensin-converting Enzyme 2 (ACE2)
7%
Neutralizing Activity
7%
Fusion Loop
7%
Dendritic Cells
7%
Mac-1
7%
Antibody-dependent Enhancement
7%
Antibody Targeting
7%